Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.034
Sell
RSI(14)
42.812
Neutral
STOCH(KDJ)(9,3,3)
24.219
Neutral
ATR(14)
0.168
Low Volatility
CCI(14)
-70.066
Neutral
Williams %R
74.585
Sell
TRIX(12,20)
-0.925
Sell
StochRSI(14)
97.163
Buy
Entera Bio Ltd
ENTX0.975USD
-0.155-13.71%
Market hours （ET）Quotes delayed by 15 min
11.60MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Entera Bio Ltd
Currency: USD Updated: 2026-03-27Key Insights
Entera Bio Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 134 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Entera Bio Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Entera Bio Ltd Highlights
StrengthsRisks
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -4.56, at a medium 3-year percentile range.
Held by Steven Cohen
Star Investor Steven Cohen holds 1.19M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.48.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
10.000
Target Price
+870.87%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Entera Bio Ltd is 6.54, ranking 236 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
9.30
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.94
Operational Efficiency
2.57
Growth Potential
6.75
Shareholder Returns
7.13
Entera Bio Ltd's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Entera Bio Ltd is 6.37, ranking 285 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.56, which is -64.98% below the recent high of -1.60 and -168.45% above the recent low of -12.25.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 134/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Entera Bio Ltd is 8.00, ranking 163 out of 391 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 10.00 and a low of 10.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
10.000
Target Price
+870.87%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Entera Bio Ltd
ENTX
1
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Entera Bio Ltd is 7.11, ranking 80 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.47 and the support level at 0.88, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.092
Sell
MA10
1.183
Sell
MA20
1.256
Sell
MA50
1.376
Sell
MA100
1.797
Sell
MA200
1.910
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Entera Bio Ltd is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 22.66%, representing a quarter-over-quarter decrease of 0.00%. The largest institutional shareholder is Steven Cohen, holding a total of 1.19M shares, representing 2.60% of shares outstanding, with 56.14% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Knoll Capital Management, LLC
OPKO Health Inc
D.N.A Biomedical Solutions, Ltd.
Centillion Fund Inc
Marshall Wace LLP
Schonfeld Strategic Advisors LLC
Lieberman (Gerald M)
Toledano (Miranda Jayne)
Parkman Healthcare Partners LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Entera Bio Ltd is 2.18, ranking 244 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.57. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.53
VaR
+7.52%
240-Day Maximum Drawdown
+67.20%
240-Day Volatility
+100.01%
Return
Best Daily Return
60 days
+27.88%
120 days
+27.88%
5 years
+44.77%
Worst Daily Return
60 days
-12.71%
120 days
-12.71%
5 years
-19.20%
Sharpe Ratio
60 days
-1.08
120 days
-0.57
5 years
+0.15
Risk Assessment
Maximum Drawdown
240 days
+67.20%
3 years
+67.20%
5 years
+92.31%
Return-to-Drawdown Ratio
240 days
-0.49
3 years
+0.10
5 years
-0.16
Skewness
240 days
+1.02
3 years
+1.29
5 years
+1.90
Volatility
Realised Volatility
240 days
+100.01%
5 years
+107.86%
Standardised True Range
240 days
+14.05%
5 years
+13.83%
Downside Risk-Adjusted Return
120 days
-128.96%
240 days
-128.96%
Maximum Daily Upside Volatility
60 days
+99.21%
Maximum Daily Downside Volatility
60 days
+77.79%
Liquidity
Average Turnover Rate
60 days
+0.28%
120 days
+0.19%
5 years
--
Turnover Deviation
20 days
-48.18%
60 days
+2.39%
120 days
-29.91%
Peer Comparison
Biotechnology & Medical Research
Entera Bio Ltd
ENTX
6.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
